OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

Charity numbers: 1183175 & SC049746

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

CONTENTS

Page
Reference and administrative details of the Charity, its Trustees and
advisers		 1
Trustees' report 2 - 22
Independent auditors' report on the financial statements 23 - 27
Statement of financial activities 28
Balance sheet 29
Statement of cash flows 30
Notes to the financial statements 31 - 53

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2023

Trustees Rajeevendra Kumar Mahapatra, Chair (re-elected 30 September 2023) Nicholas Reid, Treasurer Dr Antoni Tuck Yin Chan, Trustee (re-elected 30 September 2023) Rachel Davis (elected 30 September 2023) Gillian Eames, Trustee Paul Curry, Trustee Dr Jacqueline Harris, Trustee (retired 30 September 2023) Poppy Hocken, Trustee Claire Jeffries, Trustee (re-elected 30 September 2023) Dr Lesley Jane Kay, Trustee Hannah Elizabeth Bruce, Trustee Prof Hasan Imam Syed Tahir, Trustee Alexia Katherine Dreese Granatt, Trustee Charity registered numbers 1183175 and SC049746 Principal office Unit 6 Cambridge Court 210 Shepherds Bush Road London W6 7NJ Independent BKL Audit LLP auditors 35 Ballards Lane London N3 1XW Bankers Barclays Bank UK Plc 1 Churchill Place London E14 5HP

Page 1

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees present their annual report together with the audited financial statements of the National Axial Spondyloarthritis Society for the year 1 January 2023 to 31 December 2023.

Objectives and activities

NASS’ vision is as follows:

“ The future we want to create is one where every person with axial spondyloarthritis (axial SpA) has timely and effective diagnosis, treatment and care, is empowered to make informed health choices and feels part of a supportive community.”

The Charity seeks to do this by:

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

a. Strategies for achieving objectives

In accordance with the provisions set out in its Constitution, the Trustees have adopted the following strategy for the period 2020 – 2024 to meet NASS’ principal objects:

To ensure that people with axial SpA receive timely diagnosis, effective treatment and care

Page 2

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

To empower, inform and inspire people affected by axial SpA

To foster a connected and supportive community, raising axial SpA awareness everyday, everywhere

Page 3

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

b. Activities undertaken to achieve objectives and achievements

The charity fulfils its objectives by:

c. Volunteers

NASS is heavily dependent on 250 volunteer members who provide support at branch level. Volunteer members are unpaid and NASS’ accounts do not reflect the value to NASS of the many hours work provided free to NASS. The Trustees are fully conscious of this value and recognise that the work of NASS would be considerably curtailed without the support provided by volunteer members.

Our NASS branches offer regular, physiotherapist led group exercise for anyone living with axial SpA. They are subcommittees of NASS and are led by a committee usually comprising a Chair, Treasurer and Secretary. We support our branches with a suite of resources, regular promotion of their activities, online meetings and a named member of staff who is available Monday to Friday to help with any problems or issues.

d. Main activities undertaken to further the charity’s purpose for the public benefit

NASS provides public benefit by:

In so doing, NASS improves the lives of those affected by axial SpA, particularly in relation to their ability to contribute positively to the prosperity of their communities and the country as a whole.

Page 4

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Achievements and performance

a. Summary

2023 was a very challenging year for NASS, for healthcare charities and for the sector overall. The continued impact of Covid-19 on rheumatology departments, the ongoing workforce shortage in the NHS and the cost-of-living crisis impacted significantly on our work. Demand for our services remained exceptionally high, whilst the fundraised income needed to deliver them reduced considerably.

We put in place numerous cost reduction measures, and adapted our ways of working to ensure that, as best as possible, we were able to deliver on our core objectives.

Our staff responded with an incredibly positive and collegiate approach to the financial circumstances in which we found ourselves, demonstrating tenacity, flexibility and absolute loyalty to our mission and vision.

Despite the challenges we have faced, our activities, visibility and influence have been greater than ever:

Page 5

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

b. Key performance indicators

Performance against key indicators was as follows:

c. Review of activities

Reducing diagnostic delay

In 2020, respondents to our national consultation process – healthcare professionals (HCPs), professional bodies and patients – agreed that it should be possible for every person experiencing symptoms of axial spondyloarthritis (axial SpA) to receive a diagnosis within one year of symptom onset this ambition. In June 2021 NASS published a route map which set out how to achieve a Gold Standard time of one year.

Starting from a current baseline average of 8.5 years, the achievement of this goal will require transformational change. This includes a significant increase in awareness of the condition among HCPs and the general public, a critical mass of clinical leaders who will improve health care performance in axial SpA, the widespread use of technology to ensure that axial SpA is higher within clinical reasoning and to support diagnosis, the routine use of pathways to ensure that patients are referred directly to rheumatology for assessment, and consistent use of agreed national protocols for imaging.

Above all, to attain such a dramatic change in time to diagnosis we must win hearts and minds, build a social movement of people who want to work with us to create change, and demonstrate proof of concept for our ideas.

2023 was the second full year of implementation of our route map.

Making the case for change

We continued to make the case for change through research and audit:

Page 6

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

progress in raising awareness of axial SpA among radiology teams and of the importance of spinal MRI in the diagnostic process. It also highlighted a concern in the emergence of the reliance on non-musculoskeletal outsourcing for the interpretation of images and the lack of associated quality control. The reliance on non-musculoskeletal radiologists is of concern as the survey showed that non-MSK radiologists generally are less familiar with the term axial SpA and with the 2019 BRITSpA imaging guidance, which may be result in poorer patient outcomes. Finally, the study highlighted that collaboration between rheumatology and radiology makes an important contribution to the quality of care that patients receive.

We brought these results to the attention of Ministers, other Parliamentarians, policymakers and healthcare professionals:

Raising public awareness about early diagnosis

Raising public awareness about axial SpA and inflammatory back pain is key to earlier diagnosis. We continued to run a national social media campaign featuring case studies of people living with axial SpA. 33,058 people visited our campaign website. Our social media adverts reached 842,546 people which drove 172,112 engagements (likes, comments) and led to 9,883 views of our campaign videos. We also helped people start their diagnosis journey with 8,042 people completing the NASS symptom checker. We also made preparations for a second phase of our public awareness campaign to be delivered in Belfast in early 2024.

Raising clinical visibility for axial SpA in primary care

The lengthiest part of the delay in diagnosis is in primary care. In 2022 we sought to address this by creating a cadre of clinical champions in primary care and community services whose work would ensure that axial SpA is higher within the clinical reasoning of primary care professionals so that patients who present with suspected axial SpA are identified at the first presentation and urgently referred to rheumatology.

Page 7

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Engaging healthcare professionals (HCPs)

We launched an online peer to peer network in April to provide a space for HCPs to share their experiences, knowledge and skills in aiming to reduce diagnostic delay. BY December, a total of 124 HCPs had signed up, with members either working in the NHS or Private Practice, including Physios, Chiropractors and Osteopaths. We ran nine monthly sessions with members reporting to gain benefit from connecting with others and learning from their experiences.

We created an online toolkit which aims to have all the necessary resources for HCPs to reduce the delay to diagnosis all in one place. In collaboration with the Champions in Primary Care we compiled a 15minute education presentation specifically for use in Primary Care. We created a larger presentation that contained the background of the Act on Axial SpA campaign as well as our NASS resources which HCPs can tailor to their audience.

We created the Change Maker award to acknowledge the work of those who have demonstrated significant progress in implementing the gold standard time to diagnosis and made 23 awards at a Parliamentary reception.

We are seeing reductions in the time to diagnosis in some parts of the UK

Through our time to diagnosis audit and our Aspiring to Excellence programme (see below) we can see localised improvements in time to diagnosis. For example, since joining Aspiring to Excellence two years ago, the rheumatology team at the Royal Free NHS Foundation Trust has achieved a reduction in time to diagnosis from a median of six years to five years by implementing the recommendations in Act on Axial SpA . Since joining, Bedfordshire Hospitals NHS Foundation Trust has reduced the delay by 2.7 years. The Royal Berkshire NHS Trust has shown with a recent sample of patients that it has achieved the Gold Standard of diagnosis within one year of symptom onset. We will use this new evidence to encourage and support the improvement activities of others and continue to press the case for support at national level.

Page 8

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Improving healthcare quality across the patient pathway

In 2019 we established the Aspiring to Excellence programme. In partnership with the NHS Transformation Unit, we teach rheumatology teams the fundamentals of healthcare quality improvement and, through learning sessions, coaching and webinars, we encourage participating teams to share their experiences and data.

In 2023 the programme continued to grow and generate new data and momentum. We welcomed four more rheumatology departments into the programme. We held a celebration day to reflect on progress from the first and second cohorts and to share data from the teams from their improvement work. We continued to promote the existing podcast series and launched a blog series asking teams to reflect on their experiences and learning.

We drew on the results of research we commissioned to look at the values and needs of people with axial SpA from which we created a long list of values-based quality standards in the diagnosis, treatment and care of axial SpA. Our supporters voted on their top ten which we developed into a poster. We created a toolkit to support HCPs in applying these standards to their services.

We began work on a programme to develop a gold standard approach to treatment, long-term care. We shared our proposal with a group of stakeholders and invited HCPs and people living with axial SpA to contribute. In partnership, we created a shared vision of the project, and agreed the workstreams, the review methodology and stakeholder agreement strategy.

Helping people to live well with axial SpA

Axial SpA is a condition that requires a great deal of information, support and guidance for people to manage their symptoms effectively and ensure optimal long-term outcomes There are few formal patient education programmes for axial SpA and many people report feeling isolated and have never met anyone else with the condition. NHS backlogs and the rheumatology workforce crisis are such that this need is ongoing.

Helpline

Numbers contacting the NASS Helpline reduced since the unprecedented levels seen during COVID19. We supported 5,000 enquiries in 2023. The trend towards more complex problems and longer calls continued. This seems to be related in part to staffing shortages and the workload in rheumatology departments, with callers reporting long waits for appointments and calls to department helplines resulting in a lack of response. The NASS Helpline is often the only place people can turn to for help and support and we responded to 80% of queries within 1 working day. The worsening economic situation has also led to more people seeking help with benefits as Welfare Rights organisations become overwhelmed. We supported 324 people with claims for disability benefits which we predict will result in people receiving £1.3 million in disability benefits.

NASS Branches

2023 saw branches make a strong return to pre-COVID activity. We had 58 branches meeting face to face for group physiotherapy sessions, of which 36 were able to offer hydrotherapy. This includes our two new branches, NASS Nottingham, and NASS Coventry. We also had 10 branches operating online, including our new NASS online branch. Some of these are in the final stages of negotiation to return to face-to-face sessions. We supported all branches in logistical conversations with hospitals, health professionals and venues and with promotion of their branch. This is despite of being unable to recruit a much-needed Branch Development Officer in 2023 due to funding.

Page 9

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Information provision

We sent guidebooks to 122 rheumatology and physiotherapy departments, GP practices, osteopath and chiropractor clinics. We updated the website information on a rolling basis, added new information pages, and kept our Covid-19 information page updated.

- Supported self management programme

We support people through education and empowerment, and by creating a supportive community, we aim to reduce the isolation people with axial SpA experience.

In developing our self-management work, we held consultations with patients and healthcare professionals, which identified that our supported self-management programme should: empower patients with axial SpA to live well with their condition; be co-designed with people living with axial SpA and healthcare professionals; be easily accessible; reduce isolation; and leave a legacy.

Our supported self-management programme comprises:

We ran 12 online sessions in partnership with 26 NHS rheumatology departments, reaching nearly 450 people living with axial SpA.

We ran 20 Facebook Live sessions with over 91,000 views. The My AS, My Life webpages were visited nearly 20,000 times. We continued to get excellent engagement with the live sessions and the video library is an excellent resource to signpost people to. Sessions were run on: information about the condition; tips for daily life with axial SpA; exercise taster sessions; emotional wellbeing; and managing pain.

We launched Your SpAce which is aimed at people at the start of their axial SpA journey, as well as those who are struggling, and people who feel isolated. It was developed in collaboration with people with axial SpA and HCPs and focussed initially on pain, fatigue and flares. We made a series of videos and resources focusing on these topics and promoted them through AS News , social media and via rheumatology departments. We sent promotional packs to over 120 rheumatology department containing posters to display in clinics and promotional postcards to hand to patients. In the nine months since launch, the 14 videos had nearly 12,000 views and the webpages had over 22,000 views. We received excellent feedback:

As part of Your SpAce we wanted to provide a safe space for people to meet and share experiences and ask questions. We ran 12 on-line meetups, with 300 attendees. These have also been very positively evaluated:

Page 10

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Raising the profile of axial SpA within Government

In 2019 we worked with Parliamentarians to create an All Party Parliamentary Group (APPG) on axial SpA with the aim of providing national level oversight of the implementation of NICE Guideline 65 concerning the diagnosis and treatment of spondyloarthritis.

The APPG met twice in 2023. In April, women and axial SpA was discussed, whilst a second meeting in October reflected on the formation of Integrated Care Systems (ICS) one year on, and the opportunities to ensure that axial SpA is a local priority.

We responded to a call for evidence for the Major Conditions Strategy and subsequently met with the team developing the document and the Musculoskeletal Policy Team at the Department of Health and Social Care. We met with the Secretary of State for Health and Social Care representing the wider musculoskeletal community to discuss this. In Wales we continued to develop our relationship with the Musculoskeletal Clinical Leads within Welsh Government and contributed to the development of the MSK Quality Standards.

Health inequalities

Our work in health inequalities focused on sex, gender and gender identity. We secured funding for a research study and commissioned Headstrong Thinking to conduct a series of focus groups and interviews.

Media engagement

NASS CEO was quoted by The Guardian newspaper on the impact that missing a medicines delivery has on people with axial SpA. He was also quoted by The Pharmaceutical Journal in a news story about a Care Quality Commission investigation into this area.

We launched the findings from our patient values research which uncovered large disparities in the experience of men and women with axial SpA as they navigate diagnosis and care. The research was covered by The Times (print and online), with a combined reach of 43 million.

Social media

We continued to reach and engage broader audiences on social media, creating a sense of community and sharing stories about people’s experiences of life with axial SpA. For example:

Page 11

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

We had to scale back our plans in the second half of the year as interim management arrangements were put in place for communications as a consequence of the need to make cost reductions. Nevertheless, we were able to grow our followship.

Alliances

We continued to provide the secretariat for the newly formed Aquatic Physiotherapy and Hydrotherapy Alliance. It worked on key areas - policy and parliamentary, rapid response, research and supporting NHS services. The alliance developed a document outlining the benefits of hydrotherapy to help departments maintain and retain services and a suite of materials to help develop services further.

We became key members of the MSK Partnership, a multi-professional partnership inclusive of all MSK professions, MSK sub-specialties, professional bodies, arms-length organisations, the third sector, public and patients. This gave us the opportunity to be partners at the MSK Conference, part of Therapy Expo.

We continued to build our relationship with the MSK Clinical Leads in Wales and had an exhibition stand at the launch of the Wales MSK Quality Standards.

Membership

Our members are the lifeblood of the society. Due to the need for cost reduction, we were without a Membership Officer for 18 months, until the end of July 2023. Membership numbers remained constant at around 4,100 which was encouraging in light of the macro-economic environment and its impact on people’s disposable income. We held another successful Members Day, but did so online only due to budget constraints, and held NASS Voices events in Glasgow and Cardiff.

d. Factors relevant to achieve objectives

The challenging macro-economic environment has impacted negatively on our fundraised income affecting the achievement of some of our communications objectives. Conversely, the strength of our long-term funding relationships with pharmaceutical companies has provided the stability necessary to deliver our larger multi-year projects. We have excellent relationships with a wide range of healthcare professionals, professional bodies, health consortia and other charities, all of which has enriched our work and strengthened its impact.

Page 12

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

e. Fundraising activities and income generation

Raising funds for NASS

Thank you to everyone who supported us in 2023 by donating or fundraising. We don’t receive public funding and couldn’t do our work without the generosity of our supporters. The money we raise ensures that we’re here to transform axial SpA diagnosis and care, and offer practical support and advice to anyone affected by the condition.

At the national level we exceeded our target by £8,741 and our income in 2023 amounted to £873,253 (£908,425 in 2022).

Income at branch levels amounted to £154,399 in 2023 (£118,099 in 2022)

In 2023 our fundraising activities included:

Community and events fundraising: 38 people took on a running, trekking, swimming, cycling or rowing challenge, and 55 people joined Gaming for AS, Walk Your AS Off, Stretch-Tember or the Winter Walks Challenge.

Donations and individual giving : Despite the cost-of-living crisis, 246 people gave a one-off cash gift, 122 people gave a regular donation, 96 people donated in memory of someone, and 230 people - including 14 branches - donated to the Winter Appeal. Whether you gave a one-off cash gift, a regular donation, a gift in memory of someone, or gave to our Winter Appeal, we want to thank you for your generosity.

Corporate Donations: We extend our thanks to the corporate companies that have generously supported us through direct donations and matched donations. Your support is invaluable in helping us continue our mission.

Capital Group David Lloyd Leisure Dot Origin Ltd Estee Lauder Google Lloyds TSB Foundation Microsoft Morrisons Foundation Palo Alto Networks Paul Berg and Taylor Robert W Baird Group Sony Interactive Entertainment Europe The Generation Foundation Working at Height Limited

Legacy fundraising : We are extremely grateful to everyone who leaves a gift in their Will. In 2023 we received income from five legacies totalling £79,443.

Page 13

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Funding from pharmaceutical companies: We would also like to thank the following companies that supported us in 2023:

AbbVie Ltd £30,850 Biogen Idec Ltd £30,000 Eli Lilly and Company £30,000 Janssen-Claig Limited £5,000 Novartis Pharmaceuticals UK Ltd £77,862 UCB Pharma Ltd £247,582

Any relationship NASS has with a pharmaceutical company is underpinned by the following principles:

Trading: 450 people took part in a raffle, 46 people made a bid in the online Christmas auction and 19 people bought a card from Making a Difference Cards. We want to thank everyone for taking part and supporting our work.

Page 14

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Trust fundraising : We would like to thank the following charitable Trusts that supported us, collectively giving £63,200.

Clifford Chance UK Foundation Forest Trust Garfield Weston Foundation Help for Health John Coates Charitable Trust Oakdale Trust Pentwyn Trust Pilkington Charities Fund Souter Charitable Trust The Bernadette Charitable Trust The February Foundation The Hamilton Wallace Trust The Joan Ainslie Charitable Trust The Mary Homfray Charitable Trust The Medicash Foundation The Michael and Anna Wix Charitable Trust The Simon Gibson Charitable Trust The Weinstock Fund

Enhancing Fundraising Efficiency and Stakeholder Engagement

We re-wrote and re-structured the Fundraise for NASS section of the website. We recruited a Fundraising Assistant to lead the day-to-day delivery of fundraising tasks and release more time for the Senior Fundraising Officer to spend on development and strategy. We improved Google Ads for each income stream. We started to develop higher quality stewardship journey. Staff were upskilled through training courses in Fundraising Regulations, Gift Aid, GDPR, Legacy fundraising, Individual Giving, Direct Mail and Fundraising Tech.

We partnered with People’s Fundraising to deliver online, paperless and fully branded auctions and raffles with improved stewardship, as well as the option for supporters to create their own raffles and auctions. Finally, we have been actively engaging with the Information and Support team to increase the awareness of service users that NASS depends on public support to deliver their frontline information and support services.

Fundraising responsibly

We rely on the generosity of our donors and fundraisers to do our life-changing work and have processes and policies in place to ensure that we fundraise responsibly.

Page 15

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

f. Investment policy and performance

To minimise the risk of potential loss of funds and maintain financial security, a portion of our funds is held in cash within a reputable bank.

Additionally, the charity has made strategic investments in two properties we own which provide a consistent and reliable source of income for our charitable initiatives.

NASS’ investments also included one statuette gifted by Dame Elisabeth Frink which was sold at auction in 2023. All investments are carried at market value.

Financial review

a. Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

The charity's trustees closely monitor its reserves. To ensure adequate cash reserves, the Board of Trustees decided to take out a loan against the properties owned by NASS. The loan increased the charity's free cash reserves.

Trustees approved a plan for cost reductions measures proposed by the CEO.

Page 16

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

b. Reserves policy

Free reserves, defined as the balance of unrestricted funds less fixed assets, at the end of reporting period amount to £77,521 (2022 - £93,145).

The remaining funds are comprised of two investment properties (valued at £655,000) from which NASS derives rental income, branch funds of £243,190 and other restricted grants totalling £62,762.

NASS must raise income each year from voluntary sources and total income is likely to fluctuate from year to year.

We aim to hold 6-9 months free cash reserves. This working capital protects the continuity of our core work, that is, work not funded through restricted income. Core work includes our information and support service, awareness raising, campaigning and policy influencing, and the work of our branches across the UK. We have chosen a reserves level of 6-9 months having considered the level of predictability/unreliability in our income sources and the extent to which our cost base is flexible or committed. Our largest income sources (legacies and grant funding from pharmaceutical companies) come at irregular intervals, and the majority of our costs are committed, principally in the form of the staff who deliver our charitable objectives.

In 2022 our unrestricted cash reserves fell below our policy target. This was a consequence of two factors: the impact of the COVID pandemic on community and events fundraising and a lower than average legacy income. To ensure continued delivery of our charitable objectives, the Board decided to use some of the reserves below the reserves policy level. The reserves continued to decrease in 2023. Recognising the importance of strengthening our liquid reserves, in August 2023, we took a long-term bank loan. As a result, our long-term liabilities have increased. However, it has also positively impacted our cash position, and our free cash reserves at the end of the reporting period stood at £372,950, which represented 8.14 months of actual operating costs.

c. Material investments policy

The Charity holds two properties that are rented out to private tenants. Properties were chosen as a reliable source of income for the Charity and the expected income is set at £34,000 per annum given both properties are fully let.

d. Principal risks and uncertainties

The Trustees have adopted appropriate policies necessary to limit or mitigate the risks faced by NASS. The principal risks are:

Page 17

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

NASS has a safeguarding policy and set of procedures applicable to beneficiaries, staff, trustees and volunteers. Staff are trained in safeguarding and NASS branches have a training resource. The safeguarding policy and procedures are reviewed on an annual basis.

e. Financial risk management objectives and policies

Effective management of financial risk is a high priority. Given the importance of accurate financial projections and reporting, we have taken a comprehensive approach to ensure that we consistently maintain a high standard in all aspects of financial management. It includes implementing robust budgeting and costing methods, adhering to donor-imposed restrictions, maintaining strong financial systems and controls, regular reporting and ensuring adequate reserves and cash flow management. We also conduct regular audits and financial reviews to maintain transparency and accountability. We have a range of policies and procedures to achieve these objectives. We employ processes and controls to guarantee accurate financial forecasting and reporting. We follow a well-defined procedure for expenditure approval, ensuring that any spending is fully authorised, and documented accordingly. Furthermore, we take great care to keep detailed records of all restricted funds, which helps to ensure complete transparency and accountability in their utilisation.

Collaborative budgeting methods are also used to ensure our financial management practices are practical and efficient. These policies and practices reflect our commitment to sound financial management, compliance, transparency, and accountability.

f. Principal funding

In 2023, NASS received its funding from various sources, with a notable distinction between income generated at the national level and that at the branch level. 85% of our total income was raised at the national level, while 15% was generated through the efforts of our branch network, designated for their specific use (84 % of branch income came from Subscriptions, 9% from donations and legacies, 6% from fundraising activities and 1% from other income)

At the national level, our income for 2023 was diversified across various categories. Majority of our funding originated from grants provided by pharmaceutical companies (48%), designated for specific projects (restricted), along with a contribution towards general operational expenses.

Other sources of income were as follows: Donations: 17% Fundraising: 10% Membership subscriptions: 9% Legacies: 9% Investments 4% Other income 3%

Page 18

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, governance and management

a. Constitution

The charity is a Charitable Incorporated Organisation and was registered with the Charity Commission in April 2019. The rules and regulations of the CIO are set out in its Constitution, adopted by the Board of Trustees on 14 September 2019.

b. Methods of appointment or election of Trustees

The governing body of NASS is a Board of Trustees consisting of elected Trustees. Only members of NASS may be appointed as Trustees and the maximum number is twelve.

At every annual general meeting of the members of NASS, one third of the charity trustees shall retire from office. The charity trustees to retire by rotation shall be those who have been longest in office since their last appointment or reappointment. If any trustees were last appointed or reappointed on the same day those to retire shall (unless they otherwise agree among themselves) be determined by lot. The vacancies so arising may be filled by the decision of the members at the annual general meeting; any vacancies not filled at the annual general meeting may be filled by the charity trustees. Such persons shall retire at the conclusion of the next annual general meeting after the date of their appointment, and shall not be counted for the purpose of determining which of the charity trustees is to retire by rotation at that meeting.

The members or the charity trustees may at any time decide to appoint a new charity trustee, whether in place of a charity trustee who has retired or been removed in accordance with clause 15 (Retirement and removal of charity trustees), or as an additional charity trustee, provided that the limit specified on the number of charity trustees would not as a result be exceeded.

The Chair and Treasurer are approved by the Board and selected from among the trustee group. Their term of office as Chair and Treasurer is consistent with their term of office as a trustee. In advance of each AGM members of NASS are widely encouraged to nominate a fellow member as Trustee.

On appointment, new trustees are asked to spend a half day in the NASS central office for a briefing with the Chief Executive and staff to understand how the society works. Formal training is provided when required.

c. Organisational structure and decision-making policies

The Trustees meet quarterly to review matters of policy and to make appropriate judgements, directions and decisions on CIO issues. Trustees delegate authority on some matters to a Finance and General Purposes Committee consisting of the Chair, the Treasurer, up to three appointed Trustees and the Chief Executive and Head of Finance and Administration. This Committee meets four times per year. NASS also has a Medical Advisory Board which acts in advisory capacity only. Day to day management of NASS is undertaken by the Chief Executive and their staff. The trustees consider the Chief Executive and management team as comprising the key management personnel of the charity in charge of directing and running and operating the charity on a day to day basis.

Page 19

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

d. Policies adopted for the induction and training of Trustees

All new trustees receive an induction programme which includes the organisation’s structure, scheme of delegation, NASS constitution, strategic plan, business plan and budget, trustee code of conduct and CC3, The Essential Trustee . Periodic training is provided (e.g. how to read management accounts).

e. Pay policy for key management personnel

Every three years we commission external HR consultants to undertake independent benchmarking of all roles. The last review was in November 2022. Our medium term aim is to pay at the midpoint. The pay of the Chief Executive is reviewed annually by the trustees.

f. Related party relationships

There are no related party relationships. NASS is a member of various umbrella groups, including the Arthritis and Musculoskeletal Alliance, The Axial SpA International Federation, National Voices, the National Council for Voluntary Organisations, the Disability Benefits Consortium and the Prescription Charge Coalition and The Alliance (Scotland). Our membership of these bodies does not impact on the operating policies adopted by the charity.

g. Financial risk management

Further to the risks identified above, in 2024 trustees will be asked to approve an updated risk management strategy.

h. Trustees' indemnities

NASS holds Trustee Indemnity insurance through Markel UK, providing cover with a limit of 1 million pounds against any wrongful act claim made against a Trustee.

Plans for future periods

Our priority areas for 2024 are:

Reducing diagnostic delay: we will

Page 20

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Supporting the NHS to improve axial SpA care: we will

Supporting people affected by axial SpA (including self-management) : we will

Ensuring that NASS is an effective organisation: we will

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and

Page 21

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

expenditure, for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the Memorandum of Association. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

Auditors

The auditors, BKL Audit LLP, have indicated their willingness to continue in office. The designated Trustees will propose a motion reappointing the auditors at a meeting of the Trustees.

Approved by order of the members of the board of Trustees and signed on their behalf by:

Rajeevendra Kumar Mahapatra Date: 12 July 2024

Page 22

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

Opinion

We have audited the financial statements of National Axial Spondyloarthritis Society (the 'Charity') for the year ended 31 December 2023 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Page 23

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY (CONTINUED)

Other information

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

Page 24

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY (CONTINUED)

Responsibilities of trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Page 25

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY (CONTINUED)

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

Use of our report

This report is made solely to the Charity's trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the Charity's shareholders, as a body, in accordance with regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the Charity's trustees those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity and its trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

Page 26

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY (CONTINUED)

BKL Audit LLP

BKL Audit LLP

35 Ballards Lane

London

N3 1XW

Date: 12/07/2024

BKL Audit LLP are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

Page 27

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2023

Note
Income from:
Donations and legacies
3
Other trading activities
4
Investments
5
Other income
6
Total income
Expenditure on:
Raising funds
7
Charitable activities
9
Total expenditure
Net
income/(expenditure)
before net losses on
investments
Net losses on
investments
Net
income/(expenditure)
Transfers between
funds
20
Net movement in
funds
Reconciliation of
funds:
Total funds brought
forward
Net movement in funds
Total funds carried
forward		 Restricted
funds -
Branches
2023
£
142,944
9,767
156
1,532
154,399
718
151,884
152,602
1,797
-
1,797
(23,876)
(22,079)
265,269
(22,079)
243,190		 Restricted
funds - All
other
2023
£
366,056
-
-
-
366,056
-
455,514
455,514
(89,458)
-
(89,458)
8,513
(80,945)
143,707
(80,945)
62,762		 Unrestricted
funds
2023
£
359,724
89,503
35,469
22,501
507,197
123,089
426,995
550,084
(42,887)
(10,432)
(53,319)
15,363
(37,956)
770,477
(37,956)
732,521		 Total
funds
2023
£
868,724
99,270
35,625
24,033
1,027,652
123,807
1,034,393
1,158,200
(130,548)
(10,432)
(140,980)
-
(140,980)
1,179,453
(140,980)
1,038,473		 Total
funds
2022
£
879,665
112,513
29,116
5,230
1,026,524
197,412
1,321,334
1,518,746
(492,222)
(50,000)
(542,222)
-
(542,222)
1,721,675
(542,222)
1,179,453

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 31 to 53 form part of these financial statements.

Page 28

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

BALANCE SHEET AS AT 31 DECEMBER 2023

Note
Fixed assets
Tangible assets
14
Investments
16
Investment property
15
Current assets
Debtors
17
Cash at bank and in hand
Creditors: amounts falling due within one
year
18
Net current assets
Total assets less current liabilities
Creditors: amounts falling due after more
than one year
19
Total net assets
Charity funds
Restricted funds - Branches
20
Restricted funds - All other
20
Unrestricted funds
20
Total funds		 38,565
802,951
841,516
(162,614)		 2023
£
-
-
655,000
655,000
678,902
1,333,902
(295,429)
1,038,473
243,190
62,762
732,521
1,038,473		 42,464
656,510
698,974
(196,853)		 2022
£
332
27,000
650,000
677,332
502,121
1,179,453
-
1,179,453
265,269
143,707
770,477
1,179,453

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Rajeevendra Kumar Mahapatra (Chair of Trustees)

Date: 12 July 2024

The notes on pages 31 to 53 form part of these financial statements.

Page 29

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2023

Cash flows from operating activities
Net cash used in operating activities
Cash flows from investing activities
Dividends, interests and rents from investments
Proceeds from the sale of tangible fixed assets
Proceeds from sale of investments
Net cash provided by investing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
The notes on pages 31 to 53 form part of these financial statements		 2023
£
99,248
35,625
-
11,568
47,193
146,441
656,510
802,951		 2022
£
(267,350)
28,209
885
-
29,094
(238,256)
894,766
656,510

Page 30

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. General information

The National Axial Spondyloarthritis Society is a CIO incorporated under articles of association dated 29th April 2019 in England & Wales with charity registration number 1183175. It was subsequently registered with the Scottish Charity Regulator on 19th November 2019 with Scottish charity registration number SC049746.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended).

National Axial Spondyloarthritis Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Charity has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Charity, can be reliably measured.

Grants are included in the Statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

Page 31

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

2.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets costing £1,000 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment - 25% Straight Line

Page 32

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as ‘Gains/(Losses) on investments’ in the Statement of financial activities.

Investments held as fixed assets are shown at cost less provision for impairment.

2.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.8 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.9 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

2.10 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Page 33

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.11 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements. Due to the significant nature of branches on the accounts, the Restricted branch fund is displayed separately throughout the accounts.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

Donations
Legacies
Charity grants
Subscriptions
Donations
Legacies
Charity grants
Subscriptions		 Restricted
Funds -
Branches
2023
£
12,393
1,000
-
129,551
142,944
Restricted
Funds -
Branches
2022
£
6,822
-
-
102,899
109,721		 Restricted
funds - All
other
2023
Unrestricted
funds
2023
£
£
9,500
137,086
100
78,343
356,456
63,288
-
81,007
366,056
359,724
Restricted
funds - All
other
2022
Unrestricted
funds
2022
£
£
37,241
112,084
-
72,657
413,583
54,346
-
80,033
450,824
319,120		 Total
funds
2023
£
158,979
79,443
419,744
210,558
868,724
Total
funds
2022
£
156,147
72,657
467,929
182,932
879,665

Charity grants includes Pharmaceutical Industry grants of £419,744 (2022: £466,536) and other grants of £Nil (2022: £1,393).

Page 34

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

4. Income from other trading activities

Income from fundraising events

Fundraising events
Restricted
Funds -
Branches
2022
£
Fundraising events
5,296		 Restricted
Funds -
Branches
2023
Unrestricted
funds
2023
£
£
9,767
89,503
Restricted
funds
2022
Unrestricted
funds
2022
£
£
221
106,996		 Total
funds
2023
£
99,270
Total
funds
2022
£
112,513

5. Investment income

Rental income
Bank Interest
Rental income
Bank Interest
Profit on disposal of fixed assets		 Restricted
funds -
Branches
2023
Unrestricted
funds
2023
£
£
-
31,985
156
3,484
156
35,469
Unrestricted
funds
2022
£
28,023
186
907
29,116		 Total
funds
2023
£
31,985
3,640
35,625
Total
funds
2022
£
28,023
186
907
29,116

Page 35

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

5. Investment income (continued)

6. Other incoming resources

Other Income
Other Income		 Restricted
Funds -
Branches
2023

£
1,532
Restricted
Funds -
Branches
2022
£
3,082		 Unrestricted
funds
2023
£
22,501
Unrestricted
funds
2022
£
2,148		 Total
funds
2023
£
24,033
Total
funds
2022
£
5,230

7. Expenditure on raising funds

Fundraising trading expenses

Expenditure on raising donations and legacies
Staging fundraising events
Fundraising for membership
Staff remuneration
General fundraising expenditure
Allocated centrally incurred fundraising and governance
costs		 Restricted
funds -
Branches
2023
Unrestricted
funds
2023
£
£
-
7,444
718
2,235
-
936
-
66,281
-
21,964
-
24,229
718
123,089		 Total
funds
2023
£
7,444
2,953
936
66,281
21,964
24,229
123,807

Page 36

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

7. Expenditure on raising funds (continued)

Fundraising trading expenses (continued)

Expenditure on raising donations and legacies
Staging fundraising events
Fundraising for membership
Staff remuneration
General fundraising expenditure
Allocated centrally incurred fundraising and governance
costs		 Restricted
funds -
Branches
2022
£
-
355
-
-
-
-
355		 Unrestricted
funds
2022
£
15,292
7,936
1,529
118,368
26,442
27,490
197,057		 Total
funds
2022
£
15,292
8,291
1,529
118,368
26,442
27,490
197,412

8. Analysis of grants

Grants, A Connected and Supportive
Community
Grants, Empower, Inform and Inspire		 Grants to
Institutions
2023
£
1,003
-
1,003		 Grants to
Individuals
2023
£
179
300
479		 Total
funds
2023
£
1,182
300
1,482		 Total
funds
2022
£
-
-
-

Page 37

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

9. Analysis of expenditure on charitable activities

Summary by fund type

Every Patient Every Time
A Connected and Supportive Community
Empower, Inform and Inspire
Every Patient Every Time
A Connected and Supportive Community
Empower, Inform and Inspire		 Restricted
funds -
Branches
2023
£
-
151,884
-
151,884
Restricted
Funds -
Branches
2022
£
-
126,688
-
126,688		 Restricted
funds - All
other
2023
Unrestricted
funds
2023
£
£
345,248
189,381
64,676
63,291
45,590
174,323
455,514
426,995
Restricted
funds - All
other
2022
Unrestricted
funds
2022
£
£
492,734
180,078
87,018
209,034
53,979
171,803
633,731
560,915		 Total
2023
£
534,629
279,851
219,913
1,034,393
Total
2022
£
672,812
422,740
225,782
1,321,334

10. Analysis of expenditure by activities

Every Patient Every Time
A Connected and Supportive Community
Empower, Inform and Inspire		 Activities
undertaken
directly
2023
£
445,170
263,757
161,836
870,763		 Grant
funding of
activities
2023
£
-
1,182
300
1,482		 Support
costs
2023
£
89,459
14,912
57,777
162,148		 Total
funds
2023
£
534,629
279,851
219,913
1,034,393

Page 38

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

10. Analysis of expenditure by activities (continued)

Every Patient Every Time
A Connected and Supportive Community
Empower, Inform and Inspire		 Activities
undertaken
directly
2022
£
603,911
362,638
166,683
1,133,232		 Support
costs
2022
£
68,901
60,102
59,099
188,102		 Total
funds
2022
£
672,812
422,740
225,782
1,321,334

Analysis of direct costs

Staff costs
Other staff costs
Courier & distribution of materials
Literature, brochures and information
Promotion of activities and materials
Organising professional events
External technical providers
Attending professional events
Branch network expenditure		 Every
Patient
Every Time
2023
£
235,262
10,045
1,835
7,494
2,348
99,275
87,237
1,674
-
445,170		 A
Connected
and
Supportive
Community
2023
£
40,892
1,264
3,791
4,500
54,797
6,219
2,391
-
149,903
263,757		 Empower,
Inform and
Inspire
2023
£
152,275
804
2,841
4,590
808
343
175
-
-
161,836		 Total
funds
2023
£
428,429
12,113
8,467
16,584
57,953
105,837
89,803
1,674
149,903
870,763

Page 39

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

10. Analysis of expenditure by activities (continued)

Analysis of direct costs (continued)

Staff costs
Other staff costs
Courier & distribution of materials
Literature, brochures & information
Promotion of activities and materials
Organising professional events
External technical providers
Attending professional events
Branch network expenditure		 Every
Patient
Every Time
2022
£
212,784
5,301
928
36,750
8,855
62,057
247,874
29,362
-
603,911		 A Connected
and
Supportive
Community
2022
£
162,848
1,000
4,123
25,432
21,472
21,075
-
-
126,688
362,638		 Empower,
Inform and
Inspire
2022
£
135,682
268
1,389
16,073
2,364
-
10,907
-
-
166,683		 Total
funds
2022
£
511,314
6,569
6,440
78,255
32,691
83,132
258,781
29,362
126,688
1,133,232

Analysis of support costs

Staff costs
Depreciation
Other staff costs
Premises costs
Travel & accomodation expenses
IT and Communications
Office costs
Insurance, legal & professional
Other support costs
Bank charges& interest
Governance costs		 Every
Patient
Every Time
2023
£
38,666
159
1,996
7,239
796
12,425
2,409
11,910
669
7,427
5,763
89,459		 A
Connected
and
Supportive
Community
2023
£
6,444
27
333
1,206
133
2,071
402
1,985
112
1,238
961
14,912		 Empower,
Inform and
Inspire
2023
£
24,972
103
1,290
4,674
514
8,025
1,556
7,692
432
4,797
3,722
57,777		 Total
funds
2023
£
70,082
289
3,619
13,119
1,443
22,521
4,367
21,587
1,213
13,462
10,446
162,148

Page 40

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

10. Analysis of expenditure by activities (continued)

Analysis of support costs (continued)

Staff costs
Depreciation
Other staff costs
Premises costs
Travel & accomodation expenses
IT and communications
Office costs
Conference costs
Insurance, legal & professional
Other support costs
Bank charges& interest
Governance costs		 Every
Patient
Every Time
2022
£
16,970
1,837
1,428
21,956
586
8,442
2,690
660
8,844
146
303
5,039
68,901		 A Connected
and
Supportive
Community
2022
£
19,484
1,405
1,091
16,791
450
7,357
2,058
504
6,763
113
232
3,854
60,102		 Empower,
Inform and
Inspire
2022
£
26,398
1,188
924
14,207
379
4,562
1,740
427
5,723
94
196
3,261
59,099		 Total
funds
2022
£
62,852
4,430
3,443
52,954
1,415
20,361
6,488
1,591
21,330
353
731
12,154
188,102

11. Auditors' remuneration

2023 2022
£ £
Fees payable to the Charity's auditor for the audit of the Charity's annual
accounts 9,000 9,000
Fees payable to the Charity's auditor in respect of:
All non-audit services not included above 3,000 3,000

Page 41

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

12. Staff costs

Wages and salaries
Social security costs
Contribution to defined contribution pension schemes		 2023
£
409,135
39,509
60,339
508,983		 2022
£
462,676
46,171
65,319
574,166

The average number of persons employed by the Charity during the year was as follows:

2023 2022
No. No.
Employees 12 13

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

2023 2022
No. No.
In the band £100,001 - £110,000 1 1

Key management personnel consists of the CEO, Head of Communications and Fundraising, Head of Information and Support Services, Head of Policy and Health Services and the Head of Finance and Administration. The total employee remuneration and benefits of the key management personnel of the Charity were £259,185 (2022: £332,882). Please note that the Head of Communications and Fundraising left the organisation in June 2023.

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL) .

During the year ended 31 December 2023, expenses totalling £ 103.99 were reimbursed or paid directly to 1 Trustee (2022 - £67.50 to 2 Trustees) . These expenses were in relation to travel expenses.

Page 42

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

14.
Tangible fixed assets
Cost or valuation
At 1 January 2023
At 31 December 2023
Depreciation
At 1 January 2023
Charge for the year
At 31 December 2023
Net book value
At 31 December 2023
At 31 December 2022
15.
Investment property
Valuation
At 1 January 2023
Gain / (loss) on revaluation
At 31 December 2023		 Office
equipment
£
18,073
18,073
17,741
332
18,073
-
332
Freehold
investment
property
£
650,000
5,000
655,000

Investment property comprises residential flats let. The fair value of the investment property has been arrived at on the basis of a valuation carried out by an independent valuer with reference to market evidence of transaction prices for similar properties and a formal valuation made post the year end.. The valuation was made on an open market value basis.

Page 43

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

16. Fixed asset investments

At 1 January 2023
Disposals
Net book value
At 31 December 2023
At 31 December 2022
Debtors
Due within one year
Trade debtors
Other debtors
Prepayments and accrued income		 2023
£
21,057
6,410
11,098
38,565		 Other fixed
asset
investments
£
27,000
(27,000)
-
27,000
2022
£
8,840
24,655
8,969
42,464

17. Debtors

18. Creditors: Amounts falling due within one year

Bank loans
Trade creditors
Other taxation and social security
Other creditors
Accruals and deferred income		 2023
£
3,532
97,757
5,557
-
55,768
162,614		 2022
£
-
116,434
6,181
26,475
47,763
196,853

Page 44

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

19. Creditors: Amounts falling due after more than one year

2023 2022
£ £
Bank loans 295,429 -

20. Statement of funds

Statement of funds - current year

Unrestricted
funds
General Funds -
all funds
Restricted
Funds -
Branches
Branches		 Balance at 1
January
2023
£
770,477
265,269		 Income
£
507,197
154,399		 Expenditure
£
(550,084)
(152,602)		 Transfers
in/out
£
15,363
(23,876)		 Gains/
(Losses)
£
(10,432)
-		 Balance at
31
December
2023
£
732,521
243,190

Page 45

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds (continued)

Restricted
funds - All
other
Branch
Development
Fund
Fergus Rogers
Fund
Aspiring to
Excellence
Cimzia Select
Programme
Ophthalmology /
Gastroenterolog
y project
Self
Management
Programme
Gold Standard
Delay to
Diagnosis
APPG
NASS Voices
Round Table
Health
Inequalities
Total of funds		 Balance at 1
January
2023
£
7,992
2,052
42,234
150
855
21,067
35,316
517
3,493
11,900
18,131
143,707
1,179,453		 Income
£
-
-
121,000
-
-
40,962
177,694
26,400
-
-
-
366,056
1,027,652		 Expenditure
£
(1,335)
(300)
(154,623)
-
(837)
(43,957)
(199,739)
(26,229)
(9,113)
(3,600)
(15,781)
(455,514)
(1,158,200)		 Transfers
in/out
£
4,083
-
-
-
-
-
-
-
5,620
(1,190)
-
8,513
-		 Gains/
(Losses)
£
-
-
-
-
-
-
-
-
-
-
-
-
(10,432)		 Balance at
31
December
2023
£
10,740
1,752
8,611
150
18
18,072
13,271
688
-
7,110
2,350
62,762
1,038,473

Page 46

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds (continued)

Branch Network Funds

The Branch Network Funds support the local activities of NASS Branches, which offer regular physiotherapy or hydrotherapy sessions led by qualified instructors. Each Branch raises its funds and decides how to utilise them for specific activities. In the event of a branch ceasing operations, any remaining funds will be reclassified as unrestricted funds. A portion of these funds may be directed into the Branch Development Fund, to support our branches' continuous growth and development.

Branch Development Fund

The Branch Development Fund is created through donations from local NASS Branches. It aims to ensure the establishment and promotion of all Branches, and it provides start-up grants to new Branches and funds for ordering promotional materials such as posters and leaflets.

Fergus Rogers Fund

The Fergus Rogers Fund was established in memory of Fergus Rogers to assist people with axial SpA in purchasing specific items that can improve their quality of life. It is used to provide support for those in financial need to obtain essential items recommended by their healthcare professionals.

Aspiring to Excellence Fund

The Aspiring to Excellence Fund supports a multi-year quality improvement program to transform healthcare for people with axial SpA. The fund facilitates strategic partnerships between NASS, BRITSpA, and the NHS transformation unit, bringing together rheumatology teams and service improvement experts. It is utilised for various activities, including recruitment to the program, learning sessions, online coaching, podcasts, and the development of an audit tool to track the time to diagnosis.

Ophthalmology / Gastroenterology Project Fund

The Ophthalmology/Gastroenterology Project Fund supports the Gold Standard time to diagnosis program and its efforts to improve the identification and referral of suspected axial SpA in Ophthalmology and Gastroenterology. It finances the involvement of clinical associates from both specialities in gathering intelligence and understanding the current landscape. Additionally, the fund covers the development of educational materials, audits, posters, surveys, and policy reports.

The Self-Management Programme

The Self-Management Fund covers the costs of NASS's Supported Self-Management Program, which equips people with axial SpA with the skills and tools to manage their symptoms confidently. It supports various aspects of the program, including online resources, self-management sessions, and regional events held in conjunction with local NHS rheumatology departments.

Delay to Diagnosis - Gold Standard Fund

The Delay to Diagnosis - Gold Standard Fund is utilised to implement The Gold Standard Time to Diagnosis program for axial SpA. It supports various activities such as producing campaign impact reports, conducting economic analysis, delivering landscape reports, reviewing the use of MRI in diagnosis, and running public awareness campaigns.

Page 47

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds (continued)

Good Boost Fund

The Good Boost Fund was received from Innovate UK for the project 'Transforming older adult disability through virtual, peer-led community rehabilitation.' It finances the development of an online community for older adults with axial SpA. It covers staff salaries, platform development, and volunteer recruitment to lead virtual groups.

APPG (All Party Parliamentary Group) for Axial Spondyloarthritis Fund

The APPG Fund is established to oversee the implementation of the National Institute for Health and Care Excellence (NICE) guidelines for Spondyloarthritis and its Quality Standard. It supports the functioning of the parliamentary group. It is used to conduct meetings, national inquiries, and parliamentary receptions to engage with MPs on axial SpA NHS services.

NASS Voices

The NASS Voices Fund supports regional events to facilitate interactions between local people with axial SpA and their rheumatology healthcare professionals. It helps cover the costs of venue payments and other expenses for organising these events.

Round Table

The Round Table Fund supports wider policy work and national discussions on axial SpA in the UK. Although there was no activity in 2022, the fund is carried forward to continue its purpose in 2023.

Health Inequalities Fund

The Health Inequalities Fund finances a qualitative study focusing on people's experiences with axial SpA through the lens of sex, gender, and gender identity. It covers expenses related to recruitment for focus groups and data collection.

Members Day Fund

The Members Day Fund facilitates the annual Members Day and AGM events held in different towns/cities across the UK. It covers the costs of organising these events, including venue arrangements, speaker fees, workshops, and other activities for attendees.

Page 48

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds (continued)

Statement of funds - prior year

Unrestricted
funds
General Funds -
all funds
Restricted
Funds -
Branches
Branches		 Balance at
1 January
2022
£
1,103,462
298,771		 Income
£
457,380
118,099		 Expenditure
£
(757,972)
(127,043)		 Transfers
in/out
£
17,607
(24,558)		 Gains/
(Losses)
£
(50,000)
-		 Balance at
31
December
2022
£
770,477
265,269

Page 49

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds (continued)

Statement of funds - prior year (continued)

Restricted
funds - All
other
Branch
Development
Fund
Fergus Rogers
Fund
Aspiring to
Excellence
Cimzia Select
Programme
Ophthalmology /
Gastroenterolog
y project
Self
Management
Programme
Gold Standard
Delay to
Diagnosis
Good Boost
APPG
NASS Voices
Round Table
Health
Inequalities
Members Day
Total of funds		 Balance at
1 January
2022
£
4,592
2,052
149,638
150
9,205
15,241
120,584
165
3,922
1,993
11,900
-
-
319,442
1,721,675		 Income
£
-
-
115,938
-
-
49,972
200,838
9,752
27,600
2,000
-
18,459
26,486
451,045
1,026,524		 Expenditure
£
(600)
-
(223,342)
-
(8,350)
(44,146)
(286,106)
(9,917)
(31,005)
(500)
-
(328)
(29,437)
(633,731)
(1,518,746)		 Transfers
in/out
£
4,000
-
-
-
-
-
-
-
-
-
-
-
2,951
6,951
-		 Gains/
(Losses)
£
-
-
-
-
-
-
-
-
-
-
-
-
-
-
(50,000)		 Balance at
31
December
2022
£
7,992
2,052
42,234
150
855
21,067
35,316
-
517
3,493
11,900
18,131
-
143,707
1,179,453

Page 50

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

21. Summary of funds

Summary of funds - current year

General funds
Restricted funds-
Branches
Restricted funds		 Balance at 1
January
2023
£
770,477
265,269
143,707
1,179,453		 Income
£
507,197
154,399
366,056
1,027,652
Income
£
457,380
118,099
451,045
1,026,524		 Expenditure
£
(550,084)
(152,602)
(455,514)
(1,158,200)
Expenditure
£
(757,972)
(127,043)
(633,731)
(1,518,746)		 Transfers
in/out
£
15,363
(23,876)
8,513
-
Transfers
in/out
£
17,607
(24,558)
6,951
-		 Gains/
(Losses)
£
(10,432)
-
-
(10,432)
Gains/
(Losses)
£
(50,000)
-
-
(50,000)		 Balance at
31
December
2023
£
732,521
243,190
62,762
1,038,473
Balance at
31
December
2022
£
770,477
265,269
143,707
Summary of funds - prior year
General funds
Restricted
Funds-
Branches
Restricted funds		 Balance at
1 January
2022
£
1,103,462
298,771
319,442
1,721,675
1,179,453

Page 51

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

22. Analysis of net assets between funds

Analysis of net assets between funds - current year

Investment property
Current assets
Creditors due within one year
Creditors due in more than one year
Total		 Restricted
Funds -
Branches
2023
£
-
243,190
-
-
243,190		 Restricted
funds - All
other
2023
Unrestricted
funds
2023
£
£
-
655,000
62,762
535,564
-
(162,614)
-
(295,429)
62,762
732,521		 Total
funds
2023
£
655,000
841,516
(162,614)
(295,429)
1,038,473

Analysis of net assets between funds - prior year

Tangible fixed assets
Fixed asset investments
Investment property
Current assets
Creditors due within one year
Total		 Restricted
funds -
Branches
2022
£
-
-
-
265,269
-
265,269		 Restricted
funds - All
other
2022
£
-
-
-
143,707
-
143,707		 Unrestricted
funds
2022
£
332
27,000
650,000
289,998
(196,853)
770,477		 Total
funds
2022
£
332
27,000
650,000
698,974
(196,853)
1,179,453

Page 52

NATIONAL AXIAL SPONDYLOARTHRITIS SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

23. Reconciliation of net movement in funds to net cash flow from operating activities

Net expenditure for the year (as per Statement of Financial Activities)
Adjustments for:
Depreciation charges
(Gains)/losses on investments
Dividends, interests and rents from investments
Decrease in debtors
Increase in creditors
Net cash provided by/(used in) operating activities
24.
Analysis of cash and cash equivalents
Cash in hand
Total cash and cash equivalents
25.
Analysis of changes in net debt
At 1
January
2023
£
Cash at bank and in hand
656,510
Debt due within 1 year
-
Debt due after 1 year
-
656,510		 2023
£
(140,980)
332
10,432
(35,625)
3,899
261,190
99,248
2023
£
802,951
802,951
Cash flows
£
146,441
(3,532)
(295,429)
(152,520)		 2022
£
(542,222)
5,402
77,000
(28,209)
72,597
148,082
(267,350)
2022
£
656,510
656,510
At 31
December
2023
£
802,951
(3,532)
(295,429)
503,990

Page 53

Page 54

NASS

Final Audit Report

2024-07-12

Created: 2024-07-12 By: External Accounts BKL (externalaccounts@bkl.co.uk) Status: Signed Transaction ID: CBJCHBCAABAAkxAdFYwESTgKPWpFVXhDUI6BLXMQlmoE

"NASS" History

Document created by External Accounts BKL (externalaccounts@bkl.co.uk)

2024-07-12 - 17:29:25 GMT- IP address: 193.17.86.186

Document emailed to Ian Saunderson (ian.saunderson@bkl.co.uk) for signature 2024-07-12 - 17:31:37 GMT

Email viewed by Ian Saunderson (ian.saunderson@bkl.co.uk)

2024-07-12 - 17:38:42 GMT- IP address: 104.47.11.62

Signer Ian Saunderson (ian.saunderson@bkl.co.uk) entered name at signing as BKL Audit LLP 2024-07-12 - 17:43:00 GMT- IP address: 31.121.171.20

Document e-signed by BKL Audit LLP (ian.saunderson@bkl.co.uk)

Signature Date: 2024-07-12 - 17:43:02 GMT - Time Source: server- IP address: 31.121.171.20

Agreement completed.

2024-07-12 - 17:43:02 GMT